|
Fig. S4 Panels A and B show that teatment of embryos with the VEGFR tyrosine kinase inhibitor vatanalib from 20 to 55 hpf caused severe defects in intersegmental vessel (ISV, white arrows) morphogenesis. tg(tg:mCherry;kdrl:EGFP) embryos treated with vatanalib (5 μM) or DMSO (0.1%) were fixed at 55 hpf and analyzed by IF for GFP expression in the trunk/tail region. DMSO-treated embryos showed regular spacing of ISV along the trunk. In contrast, the number of ISV detectable in vatanalib-treated embryos was dramatically reduced and the remaining ISV showed an abnormal morphology. Panels C–F show results from whole-mount in situ hybridization for expression of the thyroid marker nkx2.1a in DMSO- and vatanalib-treated embryos. Examination of vatanalib-treated embryos did not reveal gross effects on size and location of the early thyroid primordium at 30 hpf. In addition, vatanalib treatment did not affect thyroid budding from the pharynx. Black arrows point to the thyroid. Scale bar: 100 μM.
Reprinted from Developmental Biology, 372(2), Opitz, R., Maquet, E., Huisken, J., Antonica, F., Trubiroha, A., Pottier, G., Janssens, V., and Costagliola, S., Transgenic zebrafish illuminate the dynamics of thyroid morphogenesis and its relationship to cardiovascular development, 203-216, Copyright (2012) with permission from Elsevier. Full text @ Dev. Biol.